[SCHEDULE 13G] Purple Biotech Ltd. American SEC Filing

Rhea-AI Filing Summary

Purple Biotech Ltd. received a Schedule 13G filing from Orca Capital AG reporting beneficial ownership of 605,000 ADSs, representing 9.9% of the outstanding American Depositary Shares (based on 6,085,450 ADSs outstanding after the issuer's registered offering). Orca Capital states sole voting and dispositive power over these ADSs and files as a German reporting person. The filing notes that the Reporting Person holds additional pre-funded and Series B warrants that are subject to a 4.99% blocker, preventing exercise that would increase beneficial ownership above 4.99% of ordinary shares under the warrants' terms. The filing is certified by Thomas Konig, Director of Orca Capital AG.

Insights

Financial Analyst

TL;DR: Orca Capital discloses a sizeable passive stake of 9.9% in PPBT with voting and dispositive control; warrant exercise is contractually limited by a 4.99% blocker.

Orca Capital's reported 9.9% stake in Purple Biotech is large enough to be material to some investors but remains below common control thresholds. The Schedule 13G format and the certification indicate a passive intent rather than an active control attempt. The disclosure that additional warrants exist but cannot be exercised beyond a 4.99% ownership threshold reduces the likelihood of near-term dilution from exercised warrants by this holder. For valuation or liquidity analysis, note the ownership was calculated on a post-offering ADS base of 6,085,450 ADSs.

Corporate Governance Expert

TL;DR: Ownership structure shows single-holder voting control of reported shares but the filing and blocker language imply passive investment, limiting governance impact.

Because Orca Capital reports sole voting and dispositive power over the 605,000 ADSs, it could influence shareholder votes if it chose to, yet filing on Schedule 13G signals passive intent under SEC rules. The existence of contractual warrant limits (the 4.99% Blocker) reduces the Reporting Person's capacity to increase its stake via warrant exercises, which constrains potential shifts in control arising from warrant conversion. The filing contains clear certification and identifies the reporting person and signatory, satisfying disclosure requirements.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Purple Biotech Ltd.

(Name of Issuer)

American Depositary Shares, each representing 200 Ordinary Shares

(Title of Class of Securities)

74638P208

(CUSIP Number)

09/04/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74638P208

1

Names of Reporting Persons

Orca Capital AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

GERMANY

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 605,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 605,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

605,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 6,085,450 American Depositary Shares ("ADSs"), each representing 200 Ordinary Shares, outstanding immediately after giving effect to the completion of the Issuer's registered offering and excludes 2,000,000 ADSs issuable upon the exercise of Series B warrants and 395,000 ADSs issuable upon the exercise of pre-funded warrants held by the Reporting Person, subject to the 4.99% blocker (defined below). Pursuant to the terms of the pre-funded and Series B warrants, as described in the Issuer's Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on September 5, 2025, the Reporting Person cannot exercise any of the pre-funded or Series B warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Ordinary Shares, including Ordinary Shares represented by ADSs (the "4.99% Blocker").

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Purple Biotech Ltd.
(b)	Address of issuer's principal executive offices: 4 Oppenheimer Street, Science Park,, Rehovot, ISRAEL, 7670104.
Item 2.
(a)	Name of person filing: Orca Capital AG
(b)	Address or principal business office or, if none, residence: Sperlring 2 85276 Hettenshausen Deutschland
(c)	Citizenship: Germany
(d)	Title of class of securities: American Depositary Shares, each representing 200 Ordinary Shares
(e)	CUSIP No.: 74638P208
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 605,000
(b)	Percent of class: 9.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 605,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 605,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orca Capital AG

Signature:	/s/ Thomas Konig
Name/Title:	Thomas Konig/Director
Date:	09/09/2025